Ken Griffin Kala Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.25 - $11.7 $9,765 - $457,037	-39,063 Reduced 22.61%	133,723 $30,000
Q2 2022 Aug 15, 2022	BUY	$0.3 - $1.31 $28,260 - $123,403	94,201 Added 119.87%	172,786 $52,000
Q1 2022 May 16, 2022	SELL	$0.61 - $1.84 $17,484 - $52,739	-28,663 Reduced 26.73%	78,585 $108,000
Q4 2021 Feb 14, 2022	SELL	$1.16 - $2.74 $3,837 - $9,063	-3,308 Reduced 2.99%	107,248 $129,000
Q3 2021 Nov 15, 2021	BUY	$2.62 - $5.43 $223,706 - $463,635	85,384 Added 339.2%	110,556 $289,000
Q2 2021 Aug 16, 2021	BUY	$5.06 - $8.15 $18,519 - $29,829	3,660 Added 17.01%	25,172 $133,000
Q1 2021 May 17, 2021	SELL	$6.24 - $9.58 $367,024 - $563,476	-58,818 Reduced 73.22%	21,512 $145,000
Q4 2020 Feb 16, 2021	BUY	$6.28 - $8.79 $326,742 - $457,334	52,029 Added 183.84%	80,330 $545,000
Q3 2020 Nov 16, 2020	SELL	$7.5 - $11.11 $1.65 Million - $2.44 Million	-219,670 Reduced 88.59%	28,301 $212,000
Q1 2020 May 15, 2020	BUY	$3.83 - $8.79 $441,844 - $1.01 Million	115,364 Added 87.0%	247,971 $2.18 Million
Q4 2019 Feb 14, 2020	SELL	$3.36 - $4.81 $391,739 - $560,793	-116,589 Reduced 46.79%	132,607 $489,000
Q3 2019 Nov 14, 2019	BUY	$3.57 - $6.58 $374,439 - $690,143	104,885 Added 72.68%	249,196 $949,000
Q2 2019 Aug 14, 2019	BUY	$4.93 - $8.8 $233,233 - $416,319	47,309 Added 48.77%	144,311 $921,000
Q1 2019 May 15, 2019	SELL	$5.19 - $8.97 $330,426 - $571,084	-63,666 Reduced 39.63%	97,002 $0
Q4 2018 Feb 14, 2019	BUY	$4.29 - $9.94 $689,265 - $1.6 Million	160,668 New	160,668 $785,000

Ticker KALA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,464,160
Market Cap $8.67M
Description
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.